Articles From: ABB Ltd 4Q 2013 -- Forecast to Abbott's MitraClip® Treatment Demonstrates Positive Results for Patients with Degenerative Mitral Regurgitation at Prohibitive Risk for Surgery


FRANKFURT--The following is a summary of analysts' forecasts for ABB Ltd (ABB) fourth-quarter results, based on a poll of 11 analysts conducted by Dow Jones Newswires (figures in million dollars, DPS and target price in franc, according to IFRS). Earnings figures are scheduled to be released February 13.
Sign-up for ABB Ltd 4Q 2013 -- Forecast investment picks
By John Revill ZURICH--ABB Ltd (ABBN.VX) said Tuesday it would sell a U.S. generator-set business, marking the first major action taken by new chief executive Ulrich Spiesshofer.
Sign-up for ABB Sells Baldor's Generator Business to Generac Holdings investment picks
2014/1/22
By Neil MacLucas ZURICH--Power-and-technology company ABB's fourth-quarter earnings will be hit by roughly $260 million in costs related to North-Sea power projects and restructuring, it said on Wednesday.
Sign-up for ABB Warns Fourth-Quarter Results Hit by Charges investment picks
Project allows mid-Atlantic island to boost wind capacity, incorporate renewable energy and maintain the stability of grid CARY, N.C. , Dec.
Sign-up for ABB's Microgrid Control Technology Enables Greening of Remote Island investment picks
2014/3/24
Abbot Downing has been recognized the “Best National Private Wealth Manager” at the inaugural Family Wealth Report Awards in New York.
Sign-up for Abbot Downing Named Best National Private Wealth Manager investment picks
Abbot Downing has opened a new office at the Wells Fargo Plaza here, as the firm expands its staff to serve its growing Houston business.
Sign-up for Abbot Downing Opens New Houston Office, Hires Karl Farmer as Portfolio Manager investment picks
ABBOTT PARK, Ill., Oct.
Sign-up for Abbott Again Recognized by Science Magazine as One of the Top Employers in the Healthcare Industry investment picks
2014/3/28
Supera Stent Addresses Growing Need in the U.S. to Treat People with Blocked Blood Vessels and Restore Blood Flow in the Upper Leg ABBOTT PARK, Ill., March 28, 2014 /PRNewswire/ -- Abbott today announced that its Supera ® Peripheral Stent System has received U.S. Food and Drug Administration (FDA) approval to treat people with blocked blood vessels in the upper leg caused by peripheral artery disease (PAD). PAD occurs when fat and cholesterol buildup causes arteries outside of the heart to narrow, which reduces blood flow to parts of the body, most commonly the legs.
Sign-up for Abbott Announces FDA Approval of Its Supera® Stent to Treat People with Peripheral Artery Disease investment picks
ABBOTT PARK, Ill., Aug.
Sign-up for Abbott Completes Acquisition of IDEV Technologies investment picks
ABBOTT PARK, Ill., Aug.
Sign-up for Abbott Completes Acquisition of OptiMedica investment picks
2014/4/10
- First-of-its-Kind Dissolving Medical Device Being Evaluated in People with Blocked Heart Vessels - Comprehensive Clinical Trial Program Demonstrates Abbott's Global Leadership in Bioresorbable Vascular Scaffold Technology - Enrollment Completions Mark Significant Progress Toward Bringing Absorb to Countries Representing More Than 50 Percent of the World's Heart Stent Market ABBOTT PARK, Ill., April 10, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb™ Bioresorbable Vascular Scaffold (BVS) in the United States , Japan and China .
Sign-up for Abbott Completes Enrollment of Absorb™ Randomized Clinical Trials in the United States, Japan and China investment picks
2013/9/12
ABBOTT PARK , Ill.
Sign-up for Abbott Declares 359th Consecutive Quarterly Dividend investment picks
2014/2/21
ABBOTT PARK, Ill., Feb.
Sign-up for Abbott Declares 361st Consecutive Quarterly Dividend investment picks
2014/4/1
ABBOTT PARK, Ill., April 1, 2014 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2014 financial results on Wednesday, April 16, 2014 , before the market opens.
Sign-up for Abbott Hosts Conference Call for First-Quarter Earnings investment picks
2014/1/6
ABBOTT PARK, Ill., Jan.
Sign-up for Abbott Hosts Conference Call for Fourth-Quarter and Full-Year 2013 Earnings investment picks
2013/9/25
ABBOTT PARK, Ill., Sept.
Sign-up for Abbott Hosts Conference Call for Third-Quarter Earnings investment picks
By Tess Stynes Abbott Laboratories' (ABT) third-quarter earnings fell 50% on impacts from the spinoff of its AbbVie Inc. (ABBV) specialty pharmaceuticals business, although the health-care products company's remaining operations reported solid growth.
Sign-up for Abbott Labs 3rd-Quarter Profit Down 50% on Spinoff Impacts; Boosts Dividend investment picks
By Joseph Walker Abbott Laboratories continued to struggle in the fourth quarter with challenges in overseas markets, including the continued fallout from a recall that has damaged Abbott's baby-formula products in Asia and a weakened European economy that pressured sales of generic drugs.
Sign-up for Abbott Labs Reports 44% Profit Decline -- Update investment picks
2013/9/12
- Abbott Secured Highest Overall Score in its Industry Sector, More Than Doubling the Average Industry Score - Company Achieved Top Scores Across All Key Areas, Including Economic, Environmental and Social Performance - Company Included on DJSI for Ninth Consecutive Year ABBOTT PARK, Ill., Sept.
Sign-up for Abbott Named the Leading Healthcare Company on the Dow Jones Sustainability Index (DJSI) investment picks
2013/11/18
Awards Recognize Industry-Leading Companies That Demonstrate Effective Global Mergers and Acquisitions Strategy ABBOTT PARK, Ill., Nov.
Sign-up for Abbott Named Top Dealmaker for Sixth Consecutive Year by The Deal investment picks
2013/8/15
ABBOTT PARK, Ill., Aug.
Sign-up for Abbott Partners with Music Saves Lives® to Encourage Young Donors to Give the Gift of Blood investment picks
2013/9/17
Company's Commitment to Flexible Working Opportunities, Women in Leadership and Diversity Recognized for the Thirteenth Consecutive Year ABBOTT PARK, Ill., Sept.
Sign-up for Abbott Ranked Among Top 10 Best Companies by Working Mother Magazine investment picks
ABBOTT PARK, Ill., Sept.
Sign-up for Abbott Receives CE Mark for FreeStyle Optium Neo Blood Glucose and Ketone Monitoring System™ investment picks
2014/1/22
- Fourth-Quarter Ongoing EPS of $0.58 (GAAP EPS From Continuing Operations of $0.37) - - Achieved Adjusted Operating Margin Improvement in 2013 - - Launched Multiple New Products in 2013 Across Diverse Business Portfolio - - Issues Earnings Outlook for 2014 - ABBOTT PARK, Ill., Jan.
Sign-up for Abbott Reports Fourth-Quarter and Full-Year 2013 Results investment picks
2013/10/16
- Third-Quarter Ongoing EPS of $0.55 (GAAP EPS From Continuing Operations of $0.49) - - Announces 57 Percent Increase in Quarterly Common Dividend - - Confirms Full-Year 2013 Ongoing EPS Guidance Range - - Delivers Strong Gross Margin and Operating Margin Improvements - ABBOTT PARK, Ill., Oct.
Sign-up for Abbott Reports Third-Quarter 2013 Results investment picks
Company and its Foundation, the Abbott Fund, Provide $450,000 in Grants and Healthcare Products to Help People Affected by Super Typhoon ABBOTT PARK, Ill., Nov.
Sign-up for Abbott Supports Relief Efforts in the Philippines investment picks
2013/12/19
ABBOTT PARK, Ill., Dec.
Sign-up for Abbott to Present at J.P. Morgan Healthcare Conference investment picks
2013/10/25
Treatment with Minimally Invasive Device Can Improve Quality of Life for Patients with Debilitating Mitral Valve Disease Who Are at Prohibitive Surgical Risk ABBOTT PARK, Ill., Oct.
Sign-up for Abbott's First-In-Class MitraClip® Device Now Available for U.S. Patients investment picks
Results Show Treatment Provides Clinical Benefits and Improves Quality of Life for Patients with Debilitating Mitral Valve Disease Who Are at Prohibitive Surgical Risk ABBOTT PARK, Ill., Oct.
Sign-up for Abbott's MitraClip® Treatment Demonstrates Positive Results for Patients with Degenerative Mitral Regurgitation at Prohibitive Risk for Surgery investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: ABB Ltd 4Q 2013 -- Forecast to Abbott's MitraClip® Treatment Demonstrates Positive Results for Patients with Degenerative Mitral Regurgitation at Prohibitive Risk for Surgery
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity